MAPS Welcomes New Investors, Name Change for MAPS Public Benefit Corporation

Compass Pathways and Greenbrook TMS enter into three-year research collaboration agreement

Liquidia Provides Update on Clinical Pipeline Targeting PAH and PH-ILD

Seres Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Owl Therapeutics to Present Latest Data at the RESI JPM San Francisco 2024 Conference

Liquidia Corporation Announces $100 Million in New Financings

Avenue Therapeutics Reaches Final Agreement with the U.S. FDA for the Phase 3 Safety Study for IV Tramadol

Rigel Announces Collaboration with CONNECT to Conduct a Phase 2 Trial of Olutasidenib in Glioma

Sagard Healthcare Announces Closing of Credit Facility and Recent Investment Highlights

BiomX Receives Orphan Drug Designation from the U.S. Food and Drug Administration for BX004 for the Treatment of Chronic Pulmonary Infection Caused by Pseudomonas aeruginosa in Patients with Cystic Fibrosis

 1   2   3   4   5     6    7   8   9   10   11